FDA Brief

Warning letters Drugs

FDA warning letter to

Ravenscroft Apothecary, Inc. DBA Ravenscroft Escentials

High riskIssued Mar 12, 2021Posted Mar 15, 2021Center for Drug Evaluation and Research

FDA warns Ravenscroft Escentials over unapproved COVID-19 claims for aromatherapy products.

What happened

FDA reviewed www.ravenscroftescentials.com on March 3, 2021, and FTC reviewed it on March 10, 2021; FDA also reviewed the company’s Instagram page, which directs consumers to the website. The sites offered four named products under Coronavirus Support/ANTIVIRAL SUPPORT and in blog/social posts with claims that they are antiviral or help with COVID-19. FDA found these products intended to mitigate, prevent, treat, diagnose, or cure COVID-19.

What FDA found

  1. The products are unapproved new drugs because the company markets them for COVID-19 without FDA approval.

    section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. The products are misbranded drugs because their labeling makes drug claims that are not properly supported or authorized.

    section 502 of the FD&C Act, 21 U.S.C. § 352
  3. Selling or shipping these products across state lines is prohibited.

    sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The company advertised that its products can prevent, treat, or cure disease without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. 41 et seq.
  5. Deceptive claims about COVID-19 treatment, cure, prevention, or mitigation can carry civil penalties.

    COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260

What FDA wants

FDA tells the company to immediately stop selling the products for COVID-19 and review its websites, product labels, and promotional materials to remove misleading claims. Within 48 hours, the company must email FDA and FTC describing the steps taken and how it will prevent recurrence.

Who should pay attention

  • retailers and online marketplaces selling aromatherapy products
  • brands making antiviral or COVID-19 claims for essential oils
  • consumers relying on online COVID-19 product claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Medolife Rx D/B/A MedoLife Corp., AELIA, Inc. and Quanta Inc.

    FDA says Medolife sold unapproved Escozine drugs online with claims to treat cancer, HIV, and COVID-19.

    High risk
  2. www.ivermectin4covid.com

    FDA warned website ivermectin4covid.com for selling unapproved, misbranded ivermectin drugs claiming COVID-19 use.

    High risk
  3. Medical Mikes, Inc.

    FDA and FTC warned Medical Mikes over unapproved CBD claims to prevent or treat COVID-19.

    High risk
  4. Purecraft LLC

    FDA and FTC warn Purecraft LLC over CBD products marketed with unapproved COVID-19 prevention and treatment claims.

    High risk